5,6-Dichlorobenzimidazole riboside (DRB) is a nucleoside analog that inhibits various carboxyl-terminal domain kinases, including casein kinase II and cell cycle-dependent kinases (CDK), and exhibits antitumor activity. It can also trigger apoptosis[1][2][3][4][5][6][7].
体内研究
5,6-Dichlorobenzimidazole riboside, administered intraperitoneally at doses of 2.0-3.0 mg/0.25 mL water twice daily for five days, does not affect the replication of the PR8 strain of influenza virus in mice[7].
体外研究
5,6-Dichlorobenzimidazole riboside, at concentrations of 10-80 µg/mL over 72 hours, induces p53-dependent apoptosis in human colon cancer cells by inhibiting RNA synthesis[5].
5,6-Dichlorobenzimidazole riboside, at 10-100 µM for 72 hours, prompts apoptosis in human MCF-7 breast cancer cells by modulating Mcl-1 and BclxL levels and activating caspase family members in both a time- and dose-dependent manner[6].
搜索
